Advertisement

Analytic Issues for Clinical Use of B-Type Natriuretic Peptide and N-Terminal Pro B-Type Natriuretic Peptide

  • Johannes Mair
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (NT-proBNP) have emerged as the preferred candidates for diagnosis of heart failure, as well as other clinical applications. Several commercially available assays have been developed for point-of-care determination as well as for high-throughput automated laboratory platforms. Knowledge of preanalytic and analytic issues as well as sources of inter— and intraindividual variability in BNP and NT-proBNP is crucial for clinicians to allow correct interpretation of test results in routine practice. A few practical points for the clinical use of BNP and NT-proBNP include the following: Blood sampling may be performed without a standardized period of rest or posture. However, heavy physical exercise should be avoided before blood sampling. Blood for BNP determination must be collected in EDTA-coated plastic tubes, whereas for NT-proBNP serum or plasma collected in glass or plastic tubes is acceptable. Although the available assays for BNP correlate closely, owing to lack of assay standardization no two BNP assays are analytically equivalent at present. Therefore, reference and decision limits cannot be translated from one BNP assay to another. The stability of BNP is, to some extent, dependent on the assay used and requires refrigeration if samples are to be tested more than 4 h after sampling. NT-proBNP is stable for 2 d at room temperature. Because of analytic imprecision and biological variation, only NT-proBNP changes >25% from baseline and BNP concentration changes >40% correlate well with clinical course in follow-up of patients with heart failure. Erroneous test results with BNP or NT-proBNP assays are very rare but may occur from analytic inferences, such as the presence of fibrin strands or heterophilic antibodies and autoantibodies in patient samples.

Key Words

Natriuretic peptides B-type natriuretic peptide NT-proBNP imprecision interference standardization reference limit 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981;28:89–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Davies M, Espiner E, Geoff R, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440–444.CrossRefGoogle Scholar
  3. 3.
    Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000;46:1529–1534.PubMedGoogle Scholar
  4. 4.
    Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129–135.CrossRefPubMedGoogle Scholar
  5. 5.
    Shimizu H, Aono K, Mausuta K, et al. Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chim Acta 2001;305:181–186.CrossRefPubMedGoogle Scholar
  6. 6.
    Shimizu H, Masuto K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233–239.CrossRefPubMedGoogle Scholar
  7. 7.
    Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832–838.CrossRefPubMedGoogle Scholar
  8. 8.
    Wu AHB, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 2004; 50:867–873.CrossRefPubMedGoogle Scholar
  9. 9.
    Hammerer-Lercher A, Ludwig W, Falkensammer G, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performances of markers. Clin Chem 2004; 50:1174–1183.CrossRefPubMedGoogle Scholar
  10. 10.
    Fischer Y, Filzmaier K, Stiegler H, et al. Evaluation of a new, rapid bedside test for quantitative determination of BNP. Clin Chem 2001;47:591–594.PubMedGoogle Scholar
  11. 11.
    Sorti S, Prontera C, Emdin M, et al. Analytical performance and clinical results of a fully automated MEIA system for BNP assay: comparison with a POCT method. Clin Chem Lab Med 2004;42:1178–1185.CrossRefGoogle Scholar
  12. 12.
    Yeo KTJ, Wu AHB, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107–115.CrossRefGoogle Scholar
  13. 13.
    Friedl W, Mair J, Thomas S, Pichler M, Puschendorf B. Natriuretic peptides and cyclic guanosine 3′,5′-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Heart 1996;76:129–136.CrossRefPubMedGoogle Scholar
  14. 14.
    Krüger S, Graf J, Merx MW, et al. Brain natriuretic peptide kinetics during dynamic exercise in patients with chronic heart failure. Int J Cardiol 2004;95:49–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Boomsma F, Deinum J, van den Meiracker AH. Relationship between natriuretic peptide concentrations in plasma and posture during blood sampling. Clin Chem 2001;47:963–965.PubMedGoogle Scholar
  16. 16.
    Tang WHW, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003;108:2964–2966.CrossRefPubMedGoogle Scholar
  17. 17.
    Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Stability of brain type natriuretic peptide in human blood samples. Clin Chem Acta 1999;285:169–172.CrossRefGoogle Scholar
  18. 18.
    Karl J, Borgya A, Gallusser A, et al. Dedevelopment of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest 1999;59(Suppl 230):177–181.Google Scholar
  19. 19.
    Collinson PO, Barnes SC, Gaze DC, et al. Analytical performance of the NT-proBNP assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6:365–368.CrossRefPubMedGoogle Scholar
  20. 20.
    Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of NT-proBNP in a large sample of the general population. Heart 2003;89:745–751.CrossRefPubMedGoogle Scholar
  21. 21.
    Jensen KT, Carsens J, Ivarsen P, Pedersen EB. A new fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma: reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997;57:529–540.CrossRefPubMedGoogle Scholar
  22. 22.
    Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999;10:537–540.CrossRefPubMedGoogle Scholar
  23. 23.
    Maffei S, Clerico A, Iervasi G, et al. Circulating levels of cardiac natriuretic hormones measured in women during menstrual cycle. J Endocrinol Invest 1999;22:1–5.PubMedGoogle Scholar
  24. 24.
    Rutherford AJ, Anderson JV, Elder MG, Bloom SR. Release of atrial natriuretic peptide during pregnancy and immediate puerperium. Lancet 1987;I:928, 929.CrossRefGoogle Scholar
  25. 25.
    Yoshibayashi M, Kamiya T, Saito Y, et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescendence: marked and rapid increase after birth. Eur J Endocrinol 1995; 133:207–209.CrossRefPubMedGoogle Scholar
  26. 26.
    Koch A, Singer H. Normal values of BNP in infants, children, and adolescents. Heart 2003;89: 875–878.CrossRefPubMedGoogle Scholar
  27. 27.
    Mir ST, Marohn S, Läer M, et al. Plasma concentrations of NT-proBNP in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002;110:1–6.CrossRefGoogle Scholar
  28. 28.
    Knudsen CW, Riis JS, Finsen AV, et al. Diagnostic value of a rapid test for BNP in patients presenting with acute dyspnoe: effect of age and gender. Eur J Heart Fail 2004;6:55–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Wu AHB, Smith A, Wieczorek S, et al. Biologic variation for N-terminal pro and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628–631.CrossRefPubMedGoogle Scholar
  30. 30.
    Nelzi dEril GV, Tagnochetti T, Nauti A, et al. Biological variation of NT-proBNP in healthy individuals. Clin Chem 2003;49:1554, 1555.CrossRefGoogle Scholar
  31. 31.
    Hammerer-Lercher A, Falkensammer G, Ludwig W, et al. A comparison of BNP and NT-proBNP in the disease monitoring of heart failure patients. Clin Chem 2003;49(S6):A65, 66.Google Scholar
  32. 32.
    Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsertan Heart Failure Trial (Val-HeFT). Circulation 2003;107: 1278–1283.CrossRefPubMedGoogle Scholar
  33. 33.
    Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986;32:1491–1495.PubMedGoogle Scholar
  34. 34.
    Selby C. Interferences in immunoassays. Ann Clin Biochem 1999;36:704–721.PubMedGoogle Scholar
  35. 35.
    Kazmierczeak SC, Catrou PG. Analytical unterference—more than just a laboratory problem. Am J Clin Pathol 2000;113:9–11.CrossRefGoogle Scholar
  36. 36.
    Belenky A, Smith A, Zhang B, et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004;340:163–172.CrossRefPubMedGoogle Scholar
  37. 37.
    Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976–982.CrossRefPubMedGoogle Scholar
  38. 38.
    Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptide: a review. Clin Chem 2004;50:33–50.CrossRefPubMedGoogle Scholar
  39. 39.
    Luchner A, Hengstenberg C, Löwel H, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction—a marker of cardio-renal dysfunction. Hypertension 2002;39:99–104.CrossRefPubMedGoogle Scholar
  40. 40.
    McCullough PA, Duc P, Omland T, et al. BNP and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis 2003;41:571–579.CrossRefPubMedGoogle Scholar
  41. 41.
    Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600.CrossRefPubMedGoogle Scholar
  42. 42.
    Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed BNP levels in heart failure. J Am Coll Cardiol 2004;43:1590–1595.CrossRefPubMedGoogle Scholar
  43. 43.
    Shih J, Matias M. Development of an ultra-sensitive BNP assay. Poster presented at 53rd AACC annual meeting, Chicago, 2001.Google Scholar
  44. 44.
    Müller T, Gegenhuber A, Poelz W, Haltmayer M. Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay. Clin Chem 2004;50: 1104–1106.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Johannes Mair
    • 1
  1. 1.Clinical Division of CardiologyInnsbruck Medical UniversityInnsbruckAustria

Personalised recommendations